Lesley Saketkoo

Dr. Lesley Saketkoo


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LCLorenzo Cavagna
Lorenzo Cavagna
ETErnesto Trallero-Araguás
Ernesto Trallero-Araguás
FMFederica Meloni
Federica Meloni
Ilaria CavazzanaIlaria Cavazzana
Ilaria Cavazzana
JRJorge Rojas-Serrano
Jorge Rojas-Serrano
Miguel Angel Gonzalez-GayMiguel Angel Gonzalez-Gay
Miguel Angel Gonzalez-Gay
Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung disease (ILD), along with specific autoantibodies that are addressed to different aminoacyl tRNA synthetases (ARS). Until now, it has been unknown whether the presence of a different ARS might affect the clinical presentation, evolution, and outcome of ASSD. In this study, we retrospectively recorded the time of onset, characteristics, clustering of triad findings, and survival of 828 ASSD patients (593 anti-Jo1, 95 anti-PL7, 84 anti-PL12, 38 anti-EJ, and 18 anti-OJ), referring to AENEAS (American and European NEtwork of Antisynthetase Syndrome) collaborative group’s cohort. Comparisons were performed first between all ARS cases and then, in the case of significance, while using anti-Jo1 positive patients as the reference group. The characteristics of triad findings were similar and the onset mainly began with a single triad finding in all groups despite some differences in overall prevalence. The “ex-novo” occurrence of triad findings was only reduced in the anti-PL12-positive cohort, however, it occurred in a clinically relevant percentage of patients (30%). Moreover, survival was not influenced by the underlying anti-aminoacyl tRNA synthetase antibodies’ positivity, which confirmed that antisynthetase syndrome is a heterogeneous condition and that antibody specificity only partially influences the clinical presentation and evolution of this condition.

15 June 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
LSLesley Saketkoo
Lesley Saketkoo
ARAnne Russell
Anne Russell
KJKelly Jensen
Kelly Jensen
JMJessica Mandizha
Jessica Mandizha
JTJinny Tavee
Jinny Tavee
MDMarjolein Drent
Marjolein Drent
Health-related quality of life (HRQoL), though rarely considered as a primary endpoint in clinical trials, may be the single outcome reflective of patient priorities when living with a health condition. HRQoL is a multi-dimensional concept that reflects the degree to which a health condition interferes with participation in and fulfillment of important life areas. HRQoL is intended to capture the composite degree of physical, physiologic, psychological, and social impairment resulting from symptom burden, patient-perceived disease severity, and treatment side effects. Diminished HRQoL expectedly correlates to worsening disability and death; but interventions addressing HRQoL are linked to increased survival. Sarcoidosis, being a multi-organ system disease, is associated with a diffuse array of manifestations resulting in multiple symptoms, complications, and medication-related side effects that are linked to reduced HRQoL. Diminished HRQoL in sarcoidosis is related to decreased physical function, pain, significant loss of income, absence from work, and strain on personal relationships. Symptom distress can result clearly from a sarcoidosis manifestation (e.g., ocular pain, breathlessness, cough) but may also be non-specific, such as pain or fatigue. More complex, a single non-specific symptom, e.g., fatigue may be directly sarcoidosis-derived (e.g., inflammatory state, neurologic, hormonal, cardiopulmonary), medication-related (e.g., anemia, sleeplessness, weight gain, sub-clinical infection), or an indirect complication (e.g., sleep apnea, physical deconditioning, depression). Identifying and distinguishing underlying causes of impaired HRQoL provides opportunity for treatment strategies that can greatly impact a patient’s function, well-being, and disease outcomes. Herein, we present a reference manual that describes the current state of knowledge in sarcoidosis-related HRQoL and distinguish between diverse causes of symptom distress and other influences on sarcoidosis-related HRQoL. We provide tools to assess, investigate, and diagnose compromised HRQoL and its influencers. Strategies to address modifiable HRQoL factors through palliation of symptoms and methods to improve the sarcoidosis health profile are outlined; as well as a proposed research agenda in sarcoidosis-related HRQoL.

9 February 2019 in Current Treatment Options in Rheumatology
Verified
Journal Article
Closed access
PDF file
CSCourtney L. Shappley
Courtney L. Shappley
JPJulie J. Paik
Julie J. Paik
LSLesley Saketkoo
Lesley Saketkoo

15 September 2021 in Best Practice & Research Clinical Rheumatology
Verified
Journal Article
Closed access
LSLesley Saketkoo
Lesley Saketkoo
TFTracy Frech
Tracy Frech
CVCecília Varjú
Cecília Varjú
RDRobyn Domsic
Robyn Domsic
JFJessica Farrell
Jessica Farrell
VSVirginia Steen
Virginia Steen

1 July 2021 in Best Practice & Research Clinical Rheumatology
Verified
Journal Article
Closed access
HPHenrik Pettersson
Henrik Pettersson
HAHelene Alexanderson
Helene Alexanderson
JPJanet L. Poole
Janet L. Poole
JVJanos Varga
Janos Varga
MRMalin Regardt
Malin Regardt
LSLesley Saketkoo
Lesley Saketkoo

4 March 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
AGAndrea‐Hermina Györfi
Andrea‐Hermina Györfi
TFTim Filla
Tim Filla
APAmin Polzin
Amin Polzin
KTKoray TASCILAR
Koray TASCILAR
MBMaya Buch
Maya Buch
ECEustar Collaborators
Eustar Collaborators
Background: Systemic sclerosis (SSc) primary heart involvement (SSc‐pHI) is one of the leading causes of mortality in SSc. We aimed to evaluate risk factors for SSc‐pHI and its progression and the outcomes in the EUSTAR (European Scleroderma Trials and Research) cohort. Methods: SSc‐pHI was defined according to the World Scleroderma Foundation/Heart Failure Association definition. Data from 5741 patients with SSc in the EUSTAR cohort were analyzed. Additional cardiovascular data were collected from a subcohort of 838 patients with SSc. Lasso regression was used for risk factor analyses. Kaplan–Meier estimator was used for survival analyses. Progression of SSc‐pHI was evaluated by a study definition developed by rheumatology and cardiology experts. Results: Risk factors for the presence of SSc‐pHI comprised skeletal muscle atrophy (odds ratio [OR], 2.00 [95% CI, 1.00–2.68]), age (OR, 1.91 [95% CI, 1.73–2.03]), male sex (OR, 1.77 [95% CI, 1.42–2.05]), swollen joints (OR, 1.70 [95% CI, 1.47–1.98]), skeletal muscle weakness (OR, 1.38 [95% CI, 1.00–1.85]), and tendon friction rubs (OR, 1.46 [95% CI, 1.00–1.77]) (n=3276). Telangiectasia (OR, 2.10 [95% CI, 1.38–2.72]), intestinal symptoms (OR, 1.70 [95% CI, 1.04–2.42]), age (OR, 1.47 [95% CI, 1.21–1.62]), and antitopoisomerase I antibodies (OR, 1.37 [95% CI, 1.00–1.77]) were associated with an increased risk for new onset of SSc‐pHI (n=1000). Survival rate was significantly lower in patients with SSc‐pHI than in those without ( P value <0.0001, n=3768). Patients with SSc‐pHI had a lower survival rate than patients with interstitial lung disease (n=3365). Swollen joints were associated with an increased risk of progressive SSc‐pHI (OR, 2.49 [95% CI, 1.79–3.52]) (n=595). Tendon friction rubs (OR, 1.21 [95% CI, 0.94–1.90]) increased the risk of heart failure with preserved ejection fraction in patients with SSc‐pHI. Conclusions: We defined progressive SSc‐pHI and identified risk factors for new onset and progression of SSc‐pHI and for SSc‐pHI‐associated heart failure with preserved ejection fraction in the largest cohort with SSc. These findings may guide patient stratification for diagnostic workup and therapy.